- Diseases
- Acoustic Neuroma (14)
- Adrenal Gland Tumor (24)
- Anal Cancer (66)
- Anemia (2)
- Appendix Cancer (16)
- Bile Duct Cancer (26)
- Bladder Cancer (68)
- Brain Metastases (28)
- Brain Tumor (230)
- Breast Cancer (718)
- Breast Implant-Associated Anaplastic Large Cell Lymphoma (2)
- Cancer of Unknown Primary (4)
- Carcinoid Tumor (8)
- Cervical Cancer (154)
- Colon Cancer (164)
- Colorectal Cancer (110)
- Endocrine Tumor (4)
- Esophageal Cancer (42)
- Eye Cancer (36)
- Fallopian Tube Cancer (6)
- Germ Cell Tumor (4)
- Gestational Trophoblastic Disease (2)
- Head and Neck Cancer (6)
- Kidney Cancer (124)
- Leukemia (344)
- Liver Cancer (50)
- Lung Cancer (288)
- Lymphoma (284)
- Mesothelioma (14)
- Metastasis (30)
- Multiple Myeloma (98)
- Myelodysplastic Syndrome (60)
- Myeloproliferative Neoplasm (4)
- Neuroendocrine Tumors (16)
- Oral Cancer (100)
- Ovarian Cancer (170)
- Pancreatic Cancer (164)
- Parathyroid Disease (2)
- Penile Cancer (14)
- Pituitary Tumor (6)
- Prostate Cancer (144)
- Rectal Cancer (58)
- Renal Medullary Carcinoma (6)
- Salivary Gland Cancer (14)
- Sarcoma (236)
- Skin Cancer (296)
- Skull Base Tumors (56)
- Spinal Tumor (12)
- Stomach Cancer (60)
- Testicular Cancer (28)
- Throat Cancer (90)
- Thymoma (6)
- Thyroid Cancer (98)
- Tonsil Cancer (30)
- Uterine Cancer (78)
- Vaginal Cancer (14)
- Vulvar Cancer (18)
- Cancer Topic
- Adolescent and Young Adult Cancer Issues (20)
- Advance Care Planning (10)
- Biostatistics (2)
- Blood Donation (18)
- Bone Health (8)
- COVID-19 (362)
- Cancer Recurrence (120)
- Childhood Cancer Issues (120)
- Clinical Trials (628)
- Complementary Integrative Medicine (24)
- Cytogenetics (2)
- DNA Methylation (4)
- Diagnosis (230)
- Epigenetics (6)
- Fertility (64)
- Follow-up Guidelines (2)
- Health Disparities (14)
- Hereditary Cancer Syndromes (124)
- Immunology (18)
- Li-Fraumeni Syndrome (8)
- Mental Health (118)
- Molecular Diagnostics (8)
- Pain Management (62)
- Palliative Care (8)
- Pathology (10)
- Physical Therapy (18)
- Pregnancy (18)
- Prevention (898)
- Research (392)
- Second Opinion (74)
- Sexuality (16)
- Side Effects (604)
- Sleep Disorders (10)
- Stem Cell Transplantation Cellular Therapy (216)
- Support (404)
- Survivorship (322)
- Symptoms (184)
- Treatment (1776)
Is this enzyme the key to the formation of highly malignant brain cancer?
BY Ron Gilmore
2 minute read | Published June 01, 2017
Medically Reviewed | Last reviewed by an MD Anderson Cancer Center medical professional on June 01, 2017
There are many moving parts when it comes to the mechanics of how otherwise healthy cells are transformed into those that cause deadly cancers such as glioblastoma.
Research led by Zhimin Lu, Ph.D., professor of Neuro-Oncology at MD Anderson Cancer Center, has revealed new insight into how the enzyme RNF8 mediates the protein histone 3 (H3) to promote glycolysis and the formation of tumors. The results of the study were published in the May 15 online issue of the Journal of Experimental Medicine.
Lu’s team uncovered the role of RNF8-mediated H3 polyubiquitylation in the regulation of H3 stability and chromatin modification, paving the way to gene expression regulation and tumorigenesis (tumor formation).
“Disassembly of nucleosomes in which genomic DNA is packaged with histone regulates gene expression. However, the mechanisms underlying nucleosome disassembly for gene expression remain elusive,” said Lu. “We showed that activation of epithelial growth factor receptor (EGFR), which is overexpressed or mutated in nearly 60 percent of glioblastomas, results in pyruvate kinase muscle isozyme M2 (PKM2)-dependent binding of RNF8 to histone H3. RNF8 mediates H3 polyubiquitylation, leading to proteasome-dependent H3 degradation.”
In addition, H3 polyubiquitylation induces histone dissociation from chromatin, nucleosome disassembly, and binding of RNA polymerase II to MYC and CCND1 promoter regions for transcription.
“Thus, RNF8-mediated H3 polyubiquitylation promotes tumor cell glycolysis and proliferation and brain tumorigenesis,” he said.
“This suggests that receptor tyrosine kinase activation-accelerated cell growth and proliferation require disassembly of nucleosomes and a rapid turnover of histones so that the gene transcriptional machinery is maintained at a highly active state,” said Lu. “Given the broad effect of the enzyme PKM2 on gene expression by acting as a co-activator of transcriptional factors, these findings highlight the instrumental role of PKM2/RNF8-mediated modification, which is instrumental for epigenetic regulation of gene expression and tumorigenesis.”
MD Anderson team members included Yan Xia, Ph.D.; Xinjian Li, Ph.D.; Yugang Wang, Ph.D.; Yanhua Zheng, Ph.D.; and Jong-Ho Lee, Ph.D. Participating institutions included Shanghai Institute for Biological Sciences, Shanghai, China; Shanghai Jiaotong University, Shanghai, China; and Ocean University of China, Qingdao, China.